Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have already completed a full course of treatment for localised prostate cancer (such as surgery to remove the prostate, radiation therapy, or brachytherapy), and where standard curative treatment options have been exhausted
- People who have previously had targeted radiation treatment (called SBRT) for a small number of visible cancer spread sites, as long as the prostate-specific antigen (PSA) blood marker has continued to rise after that treatment
- People whose testosterone levels are at or above normal non-castrate levels (at least 5 nmol/l); previous hormone-lowering treatment is allowed as long as testosterone levels have returned to normal before joining the trial
- People who show no signs of cancer that has spread to distant parts of the body, based on standard scans (CT scan and bone scan) or a specialised scan called a PSMA PET CT
- People who have enlarged lymph nodes detected on a PSMA PET CT scan, provided those lymph nodes are below a certain size threshold depending on their location in the body (confirm with trial site for exact size limits)
- People whose PSA blood level is 1 ng/ml or higher after prostate removal surgery, or 2 ng/ml or more above their lowest recorded PSA level after radiation therapy, with testosterone at normal levels; a rising PSA must be confirmed by at least two measurements taken at least two weeks apart
- People who have declined starting hormone therapy and/or a type of medication called an androgen receptor pathway inhibitor (ARPI), or whose treating doctor has assessed that starting these treatments is not immediately necessary
Who may not be able to join:
- People who have a pre-existing known liver disease, whether long-term (chronic) or short-term (acute)
- People who have a known history of systemic lupus erythematosus or any form of lupus, including lupus affecting the skin, lupus caused by medication, or lupus affecting the kidneys
- People whose prostate cancer is of a rare type known as pure neuroendocrine or small-cell variant (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Stefanie Fischer, PD MD, HOCH Health Ostschweiz
Phone: +41 31 389 91 91
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prostate specific antigen Progression-free rate (PSA-PFR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.